Australia · Delayed Price · Currency is AUD ImpediMed Earnings Call Transcripts
Fiscal Year 2026
-
A new CEO with strong U.S. medtech experience has been appointed to accelerate commercial execution, building on robust operational foundations and expanded reimbursement coverage. The company achieved solid U.S. sales growth in Q3 and continues to focus on cost discipline.
-
Quarterly revenue hit a record AUD 3.9M, up 18% year-on-year, with strong rest of world sales and improved cash flow. Over 700 sales opportunities are in the pipeline, and new FDA clearances and product launches support growth in heart health and wellness segments.
-
SOZO platform adoption is expanding across lymphedema, heart failure, and body composition, with record revenue and ARR growth. Reimbursement coverage has surged, and a revamped sales team is expected to drive a rebound in U.S. sales next quarter.
Fiscal Year 2025
-
The meeting reviewed strong revenue and ARR growth, highlighted expansion into new U.S. health markets, and discussed board expertise and governance. Shareholders engaged on sales metrics, staffing, and global strategy, with management outlining plans for further growth and operational efficiency.
-
Record TCV and ARR growth driven by strong U.S. sales, expanded reimbursement, and disciplined cost management. Strategic expansion into body composition and heart failure markets positions the business for continued growth.
-
Record revenue and cash receipts were achieved, with ARR up 27% year-on-year and U.S. unit sales surpassing last year's total. A strengthened sales team and robust pipeline are expected to drive significant U.S. sales growth in Q4 and beyond.
-
Record Q2 revenue and cash receipts were achieved, with strong cost control and a positive trend in annual recurring revenue. U.S. sales remain below target, but reimbursement coverage and pipeline quality are improving, supporting confidence in reaching break-even.
-
Momentum continues with a 21% year-on-year ARR increase and a 34% rise in the opportunity pipeline. Revenue dipped 7% sequentially due to timing and currency, but cost controls and expanding reimbursement support a positive outlook.
Fiscal Year 2024
-
The meeting highlighted a strategic shift to commercialization, strong growth in core SOZO business, and expanding U.S. payer coverage. Management addressed profitability concerns, emphasizing a path to break-even with a robust sales pipeline and high renewal rates.
-
FY 2024 saw a 9% revenue decline due to lower clinical trial income, but core business revenue and ARR grew 14% and 18% respectively. Gross margin improved to 87.3%, and the company targets free cash flow break-even in FY 2025 through U.S. sales growth and cost control.
-
Q4 delivered strong revenue growth, higher contract values, and expanded U.S. market presence, with a robust sales pipeline and improved cost discipline. Break-even is targeted within two years, but a capital raise may be needed as cash outflows continue.